Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.

A novel series of chlorinated plastoquinone analogs: Design, synthesis, and evaluation of anticancer activity.

Bayrak N, Yıldırım H, Yıldız M, Radwan MO, Otsuka M, Fujita M, Ciftci HI, Tuyun AF.

Chem Biol Drug Des. 2019 Nov 30. doi: 10.1111/cbdd.13651. [Epub ahead of print]

PMID:
31785034
2.

Antileukemic Activity of Twig Components of Caucasian Beech in Turkey.

Shida W, Tateishi H, Tahara Y, Fujita M, Husham Majeed Alsaadi D, Watanabe M, Koga R, Radwan MO, Ciftci HI, Gezici S, Kurauchi Y, Katsuki H, Otsuka M, Sugimura K, Wada M, Sekeroglu N, Watanabe T.

Molecules. 2019 Oct 25;24(21). pii: E3850. doi: 10.3390/molecules24213850.

3.

Discovery and structure-activity relationship of plastoquinone analogs as anticancer agents against chronic myelogenous leukemia cells.

Ciftci HI, Bayrak N, Yıldırım H, Yıldız M, Radwan MO, Otsuka M, Fujita M, Tuyun AF.

Arch Pharm (Weinheim). 2019 Dec;352(12):e1900170. doi: 10.1002/ardp.201900170. Epub 2019 Oct 11.

PMID:
31602720
4.

Design, Synthesis and Biological Evaluation of Pentacyclic Triterpene Derivatives: Optimization of Anti-ABL Kinase Activity.

I Ciftci H, O Radwan M, E Ozturk S, Ulusoy NG, Sozer E, E Ellakwa D, Ocak Z, Can M, F S Ali T, I Abd-Alla H, Yayli N, Tateishi H, Otsuka M, Fujita M.

Molecules. 2019 Sep 30;24(19). pii: E3535. doi: 10.3390/molecules24193535.

5.

Design, synthesis, and biological activity of Plastoquinone analogs as a new class of anticancer agents.

Bayrak N, Yıldırım H, Yıldız M, Radwan MO, Otsuka M, Fujita M, Tuyun AF, Ciftci HI.

Bioorg Chem. 2019 Nov;92:103255. doi: 10.1016/j.bioorg.2019.103255. Epub 2019 Sep 7.

PMID:
31542717
6.

Anti-cancer activity of the cell membrane-permeable phytic acid prodrug.

Masunaga T, Murao N, Tateishi H, Koga R, Ohsugi T, Otsuka M, Fujita M.

Bioorg Chem. 2019 Nov;92:103240. doi: 10.1016/j.bioorg.2019.103240. Epub 2019 Sep 4.

PMID:
31525525
7.

Antiproliferative S-Trityl-l-Cysteine -Derived Compounds as SIRT2 Inhibitors: Repurposing and Solubility Enhancement.

Radwan MO, Ciftci HI, Ali TFS, Ellakwa DE, Koga R, Tateishi H, Nakata A, Ito A, Yoshida M, Okamoto Y, Fujita M, Otsuka M.

Molecules. 2019 Sep 10;24(18). pii: E3295. doi: 10.3390/molecules24183295.

8.

Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors.

Sever B, Altıntop MD, Radwan MO, Özdemir A, Otsuka M, Fujita M, Ciftci HI.

Eur J Med Chem. 2019 Nov 15;182:111648. doi: 10.1016/j.ejmech.2019.111648. Epub 2019 Aug 28.

PMID:
31493743
9.

Minimum structural requirements for inhibitors of the zinc finger protein TRAF6.

Radwan MO, Koga R, Hida T, Ejima T, Kanemaru Y, Tateishi H, Okamoto Y, Inoue JI, Fujita M, Otsuka M.

Bioorg Med Chem Lett. 2019 Aug 15;29(16):2162-2167. doi: 10.1016/j.bmcl.2019.06.050. Epub 2019 Jun 27.

PMID:
31272791
10.

Serial Femtosecond X-Ray Diffraction of HIV-1 Gag MA-IP6 Microcrystals at Ambient Temperature.

I Ciftci H, G Sierra R, Yoon CH, Su Z, Tateishi H, Koga R, Kotaro K, Yumoto F, Senda T, Liang M, Wakatsuki S, Otsuka M, Fujita M, DeMirci H.

Int J Mol Sci. 2019 Apr 3;20(7). pii: E1675. doi: 10.3390/ijms20071675.

11.

New SIRT2 inhibitors: Histidine-based bleomycin spin-off.

Ali TFS, Ciftci HI, Radwan MO, Koga R, Ohsugi T, Okiyama Y, Honma T, Nakata A, Ito A, Yoshida M, Fujita M, Otsuka M.

Bioorg Med Chem. 2019 May 1;27(9):1767-1775. doi: 10.1016/j.bmc.2019.03.003. Epub 2019 Mar 2.

PMID:
30885568
12.

Neuroprotective effects of a novel carnosine-hydrazide derivative on hippocampal CA1 damage after transient cerebral ischemia.

Noguchi K, Ali TFS, Miyoshi J, Orito K, Negoto T, Biswas T, Taira N, Koga R, Okamoto Y, Fujita M, Otsuka M, Morioka M.

Eur J Med Chem. 2019 Feb 1;163:207-214. doi: 10.1016/j.ejmech.2018.11.060. Epub 2018 Nov 28.

13.

Blockade of TGF-β/Smad signaling by the small compound HPH-15 ameliorates experimental skin fibrosis.

Luong VH, Chino T, Oyama N, Matsushita T, Sasaki Y, Ogura D, Niwa SI, Biswas T, Hamasaki A, Fujita M, Okamoto Y, Otsuka M, Ihn H, Hasegawa M.

Arthritis Res Ther. 2018 Mar 15;20(1):46. doi: 10.1186/s13075-018-1534-y.

14.

The First Pentacyclic Triterpenoid Gypsogenin Derivative Exhibiting Anti-ABL1 Kinase and Anti-chronic Myelogenous Leukemia Activities.

Ciftci HI, Ozturk SE, Ali TFS, Radwan MO, Tateishi H, Koga R, Ocak Z, Can M, Otsuka M, Fujita M.

Biol Pharm Bull. 2018 Apr 1;41(4):570-574. doi: 10.1248/bpb.b17-00902. Epub 2018 Jan 30.

15.

Introduction of H2C2-type zinc-binding residues into HIV-2 Vpr increases its expression level.

Koga R, Yamamoto M, Ciftci HI, Otsuka M, Fujita M.

FEBS Open Bio. 2017 Dec 19;8(1):146-153. doi: 10.1002/2211-5463.12358. eCollection 2018 Jan.

16.

Design, Synthesis, and Biological Evaluation of Novel 1,3,4-Thiadiazole Derivatives as Potential Antitumor Agents against Chronic Myelogenous Leukemia: Striking Effect of Nitrothiazole Moiety.

Altıntop MD, Ciftci HI, Radwan MO, Sever B, Kaplancıklı ZA, Ali TFS, Koga R, Fujita M, Otsuka M, Özdemir A.

Molecules. 2017 Dec 27;23(1). pii: E59. doi: 10.3390/molecules23010059.

17.

A Dithiol Compound Binds to the Zinc Finger Protein TRAF6 and Suppresses Its Ubiquitination.

Koga R, Radwan MO, Ejima T, Kanemaru Y, Tateishi H, Ali TFS, Ciftci HI, Shibata Y, Taguchi Y, Inoue JI, Otsuka M, Fujita M.

ChemMedChem. 2017 Dec 7;12(23):1935-1941. doi: 10.1002/cmdc.201700399. Epub 2017 Oct 4.

PMID:
28884970
18.

A clue to unprecedented strategy to HIV eradication: "Lock-in and apoptosis".

Tateishi H, Monde K, Anraku K, Koga R, Hayashi Y, Ciftci HI, DeMirci H, Higashi T, Motoyama K, Arima H, Otsuka M, Fujita M.

Sci Rep. 2017 Aug 21;7(1):8957. doi: 10.1038/s41598-017-09129-w.

19.

A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group.

Tanaka A, Radwan MO, Hamasaki A, Ejima A, Obata E, Koga R, Tateishi H, Okamoto Y, Fujita M, Nakao M, Umezawa K, Tamanoi F, Otsuka M.

Bioorg Med Chem Lett. 2017 Aug 15;27(16):3862-3866. doi: 10.1016/j.bmcl.2017.06.047. Epub 2017 Jun 20.

PMID:
28666734
20.

Zinc-binding site of human immunodeficiency virus 2 Vpx prevents instability and dysfunction of the protein.

Yamamoto M, Koga R, Fujino H, Shimagaki K, Ciftci HI, Kamo M, Tateishi H, Otsuka M, Fujita M.

J Gen Virol. 2017 Feb;98(2):275-283. doi: 10.1099/jgv.0.000701.

PMID:
28284276

Supplemental Content

Loading ...
Support Center